A multicenter observational study showed that benralizumab reduces severe asthma exacerbations and appears to be a valid add-on treatment choice for people having severe eosinophilic asthma (SEA), especially with comorbid chronic rhinosinusitis with nasal polyps (CRSwNP). Santi Nolasco and other researchers examined benralizumab's real-world efficacy in SEA with or without CRSwNP.

The study recruited 137 people having late-onset SEA and were treated with benralizumab for 24 weeks. At baseline and after four, twelve, and twenty-four weeks, recording of Asthma Control Test (ACT), dosage of oral corticosteroid, asthma aggravations, lung functions, and basophil and eosinophil count in the peripheral blood was done. At the baseline and following 24 weeks in SEA+CRSwNP, evaluation of Lund-Mackay scores and  22-item Sino-Nasal Outcome Test (SNOT-22) was done.

Overall, 57.7% (79/137) displayed the copresence of CRSwNP. Notably, the severe asthma exacerbations dropped from 4 (3-6) to 0 (0-2) following 24 weeks of therapy.  Remarkable improvements were noted as early as four weeks in ACT score, oral corticosteroid dosage, forced expiratory volume in the 1st second (FEV₁)%, FEV₁ (L), forced vital capacity (FVC)%, FEV1/FVC%, and forced expiratory flow between 25% and 75% of FVC (FEF25-75)%.

A rapid decline in basophils and eosinophils count in peripheral blood was noted. As found, the SNOT-22 dropped from 46 (39.5-64.5) to 32 (19-46) in individuals with SEA+CRSwNP. Additionally, when compared to SEA, they demonstrated improved responses regarding ACT minimal clinically important difference, FEV1%, FEV1 (L), and FEF 25-75%. Thus, benralizumab yields satisfactory outcomes in asthma people.